Titre:
  • Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Auteur:Untch, M.; Gelber, R D; Jackisch, C.; Procter, Marion; Baselga, J; Bell, Richard H; Cameron, David A; Bari, M; Smith, Ian; Leyland-Jones, Brian; Azambuja, Evandro; Wermuth, P; Khasanov, R; Feng-Yi, F; Constantin, C; Mayordomo, J I; Su, C-H; Yu, S-Y; Lluch, Ana; Senkus-Konefka, E; Price, Caroline; Haslbauer, F; Suarez Sahui, T; Srimuninnimit, V; Colleoni, Marco Angelo; Coates, Alan; Piccart-Gebhart, Martine; Goldhirsch, Aron; HERA study team,
Informations sur la publication:Annals of oncology, 19, 6, page (1090-1096)
Statut de publication:Publié, 2008-06
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Adjuvant therapy
Breast cancer
Disease-free survival
HER2-oncogene
Subgroubs
Trastuzumab
MeSH keywords:Antibodies, Monoclonal -- therapeutic use
Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- metabolism
Female
Humans
Internationality
Lymphatic Metastasis
Middle Aged
Receptor, erbB-2 -- metabolism
Receptors, Estrogen -- metabolism
Receptors, Progesterone -- metabolism
Survival Analysis
Note générale:Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdn005
info:pii/mdn005
info:scp/44849117186
info:pmid/18296421